Solana Co

Solana Co(HSDT)股票分析

$1.930

-0.156 (-8.10%)收盤時

Loading chart…
最高
2.100
開盤
2.100
成交量加權均價
1.96
成交量
601.53K
市值
2.91M
最低
1.850
成交金額
1.18M
企業價值/稅息折舊攤銷前利潤(TTM)
-0.75

Solana Company, formerly Helius Medical Technologies, Inc., is a digital asset treasury dedicated to acquiring Solana (SOL), created in partnership with Pantera and Summer Capital. It is focused on maximizing SOL per share by leveraging capital markets opportunities and on chain activity. It offers public market investors optimal exposure to Solana’s secular growth. It has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises that produce consistent on-chain yield generation. It will provide access to the Solana network. Solana DAT provides access to the blockchain market to a new kind of investor. As a global capital markets onramp, HSDT channels liquidity into the Solana ecosystem, strengthening network security and fueling on chain activity, creating a virtuous cycle that delivers value back to shareholders.

AI 分析 of Solana Co (HSDT)

賣出

Helius Medical Technologies Inc (HSDT) is not a good buy right now due to its current price of $2.015 and a very low RSI of 21.258, indicating oversold conditions. The stock has also seen a significant decline of 55.71% over the past year, which raises concerns about its long-term viability. While the forward P/E is 0, suggesting potential for future earnings, the recent performance and negative sentiment surrounding the stock indicate that it may not be a suitable investment at this time.

分析師評級(1)

買進
1 買進
0 持有
0 賣出
目前: 1.93
最低
—
平均
—
最高
—

B. Riley

2026-09-22

目標價

$4

買進

B. Riley

2026-09-03

目標價

—

買進

B. Riley

2026-04-23

目標價

$3

買進

Maxim Group

2024-10-16

目標價

—

持有

Roth MKM

2024-03-05

目標價

$24

強烈買進

估值指標

Solana Co(HSDT)目前預期本益比為 0.00,5 年平均預期本益比為 -2.35。

預期本益比

合理
5 年均值 P/E
-2.35
目前P/E
0.00
高估
4.42
低估
-9.13

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.93
目前EV/EBITDA
-0.75
高估
12.80
低估
-14.66

預期股價營收比

合理
5 年均值 P/S
48.77
目前P/S
9.87
高估
224.58
低估
-127.04

Alphio AI 對 HSDT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HSDT

$2.58

情境價格

基

基準

基準 · 50%HSDT

$2.40

情境價格

悲

悲觀

悲觀 · 25%HSDT

$2.06

情境價格

持有 HSDT 的大戶

V

VR Advisory Services Ltd.

+ 持有HSDT

+0.00%

3個月報酬率

事件時間軸

2026-10-23 (ET)

10:00:00

Webull to Launch Crypto-Linked Perpetual Futures in November

2026-10-22 (ET)

09:30:00

Solana Company Designated as Strategic Enterprise by Hong Kong Government

2026-09-25 (ET)

10:00:00

Binance Invests $100M in Circle to Boost USDC Development

2026-09-04 (ET)

10:30:00

Coinbase Files for U.S. Derivatives Registration

2026-06-30 (ET)

07:30:00

Solana Signs MoU with Alatau City for Blockchain Partnership

資訊

HSDT 常見問題 —— 由 Alphio AI 解答

Solana Company, formerly Helius Medical Technologies, Inc., is a digital asset treasury dedicated to acquiring Solana (SOL), created in partnership with Pantera and Summer Capital. It is focused on maximizing SOL per share by leveraging capital markets opportunities and on chain activity. It offers public market investors optimal exposure to Solana’s secular growth. It has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises that produce consistent on-chain yield generation. It will provide access to the Solana network. Solana DAT provides access to the blockchain market to a new kind of investor. As a global capital markets onramp, HSDT channels liquidity into the Solana ecosystem, strengthening network security and fueling on chain activity, creating a virtuous cycle that delivers value back to shareholders. It operates in the Financials sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Helius Medical Technologies Inc (HSDT) is not a good buy right now due to its current price of $2.015 and a very low RSI of 21.258, indicating oversold conditions. The stock has also seen a significant decline of 55.71% over the past year, which raises concerns about its long-term viability. While the forward P/E is 0, suggesting potential for future earnings, the recent performance and negative sentiment surrounding the stock indicate that it may not be a suitable investment at this time.

1 analysts cover HSDT: 1 rate it Buy, 0 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易